Key Insights
The biologics contract development and manufacturing organization (CDMO) market is experiencing robust growth, projected to reach \$15.32 billion in 2025 and exhibiting a compound annual growth rate (CAGR) of 12.78% from 2025 to 2033. This expansion is driven by several key factors. The increasing demand for biologics, particularly biosimilars, fuels the need for efficient and specialized CDMO services. Advancements in biotechnology, such as the development of novel therapeutic modalities like cell and gene therapies, further contribute to market growth. Furthermore, the rising prevalence of chronic diseases globally necessitates the production of large volumes of biologics, creating a significant opportunity for CDMOs. The market is segmented by product type (biosimilars, other biologics), production type (mammalian, non-mammalian), and geographic region, with North America and Europe currently dominating the market due to established infrastructure and regulatory frameworks. However, the Asia-Pacific region is projected to witness significant growth in the coming years, driven by increasing investments in healthcare infrastructure and a growing biopharmaceutical industry.
Biologics CDMO Market Market Size (In Billion)
The competitive landscape is characterized by a mix of large multinational corporations and smaller specialized CDMOs. Key players, including Samsung Biologics, Lonza Group, and WuXi Biologics, are strategically expanding their capacities and service offerings to meet the growing demand. The market's growth trajectory is subject to certain restraints, such as stringent regulatory requirements and the high cost associated with biologics manufacturing. However, the industry is continuously adapting through technological advancements and strategic partnerships to mitigate these challenges. The increasing adoption of innovative manufacturing technologies, such as continuous manufacturing and single-use systems, is expected to improve efficiency and reduce production costs, further propelling market growth. The forecast period from 2025-2033 offers considerable potential for CDMOs capable of delivering high-quality services and adapting to the evolving demands of the biopharmaceutical industry.
Biologics CDMO Market Company Market Share
Biologics CDMO Market Report: 2019-2033
This comprehensive report provides an in-depth analysis of the Biologics CDMO market, offering valuable insights for industry professionals, investors, and strategists. Covering the period 2019-2033, with a focus on 2025, this report meticulously examines market dynamics, key players, and future growth potential. The report leverages extensive data analysis and expert insights to deliver actionable intelligence, enabling informed decision-making in this rapidly evolving sector.
Biologics CDMO Market Structure & Innovation Trends
The Biologics CDMO market exhibits a moderately concentrated structure, with key players holding significant market share. However, the presence of numerous smaller, specialized CDMOs fosters competition and innovation. Market share data for 2024 reveals that the top 5 players (Wuxi Biologics, Samsung Biologics, Lonza Group, Catalent Inc, and Fujifilm Diosynth Biotechnologies) collectively hold approximately xx% of the global market. Innovation is driven by advancements in cell line development, process optimization, and analytical technologies. Stringent regulatory frameworks, particularly in the US and EU, shape manufacturing practices and product approvals. Biosimilars represent a significant market segment, driving competition and the need for cost-effective manufacturing solutions. The market also sees frequent M&A activity, with deals exceeding $xx Million in value in recent years, further shaping the competitive landscape. For example, the acquisition of Atara Biotherapeutics' facility by Fujifilm Diosynth Biotechnologies highlights the industry's focus on expanding capacity and capabilities.
Biologics CDMO Market Dynamics & Trends
The Biologics CDMO market is experiencing robust growth, with a projected CAGR of xx% during the forecast period (2025-2033). This growth is propelled by several factors, including the increasing demand for biologics, the rising prevalence of chronic diseases, and substantial investments in research and development. Technological advancements, such as single-use technologies and continuous manufacturing, are significantly impacting efficiency and cost-effectiveness. Consumer preferences for personalized medicine and advanced therapies are further driving demand. Competitive dynamics are intense, with companies focusing on capacity expansion, technological innovation, and strategic partnerships to gain a competitive edge. Market penetration of advanced modalities like cell and gene therapies is increasing rapidly, creating new opportunities for specialized CDMOs. The market is also witnessing a shift towards integrated services, with CDMOs offering a broader range of services beyond manufacturing.
Dominant Regions & Segments in Biologics CDMO Market
- Leading Region: North America holds a dominant position in the Biologics CDMO market, driven by strong R&D investments, a robust regulatory framework, and a high concentration of biopharmaceutical companies. Europe follows closely, with strong biopharmaceutical clusters and supportive government policies.
- Leading Segment (By Type): Mammalian cell-based production remains the leading segment due to its ability to produce complex biologics with high efficacy and safety profiles. However, Non-mammalian (microbial) systems are gaining traction due to their cost-effectiveness and suitability for certain biologics.
- Leading Segment (By Product Type): Monoclonal antibodies continue to be the largest segment, but the market for other biologics, including recombinant proteins, vaccines, and gene therapies, is experiencing rapid growth.
- Key Drivers:
- North America: Strong R&D investments, robust regulatory framework, established biopharmaceutical industry.
- Europe: Strong biopharmaceutical clusters, supportive government policies, focus on innovation.
- Asia Pacific: Rapidly growing biopharmaceutical industry, increasing government support, cost-effective manufacturing capabilities.
The dominance of North America is largely attributable to its well-established biopharmaceutical industry, high R&D spending, and stringent regulatory environment which fosters innovation and high-quality manufacturing standards. The robust regulatory framework ensures product safety and efficacy, attracting international investment. Europe's strong biopharmaceutical clusters and government support for the sector also contribute to its significant market share. While Asia-Pacific shows strong growth potential due to cost-effective manufacturing and a growing biopharmaceutical sector, North America currently maintains the lead.
Biologics CDMO Market Product Innovations
Recent advancements in Biologics CDMO technology focus on continuous manufacturing processes, single-use systems, and process analytical technology (PAT) to enhance efficiency, reduce costs, and improve product quality. These innovations are enabling the development and manufacturing of complex biologics, including advanced therapies like cell and gene therapies. The market sees a strong push towards flexible and scalable manufacturing platforms to cater to the diverse needs of biopharmaceutical companies. This adaptability is a key competitive advantage, allowing CDMOs to effectively manage fluctuating demands and rapidly respond to emerging market trends.
Report Scope & Segmentation Analysis
This report segments the Biologics CDMO market in several ways:
By Other Biologics: The Biosimilars segment is experiencing rapid growth, driven by patent expirations and increasing demand for cost-effective alternatives to originator biologics. The market size is expected to reach $xx Million by 2033.
By Type: Mammalian cell lines dominate the market, while Non-mammalian (Microbial) systems are gaining traction due to their cost-effectiveness for specific biologics. Growth projections for both segments are strong, with mammalian cell lines maintaining a larger market share.
By Product Type: Biologics encompass a wide range of products, with monoclonal antibodies holding the largest share. The market for other biologics, including recombinant proteins and vaccines, is also witnessing considerable growth. Competitive dynamics are highly influenced by the specialized nature of each product type.
Key Drivers of Biologics CDMO Market Growth
The Biologics CDMO market is propelled by several key factors:
Growing demand for biologics: The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is driving the demand for innovative biologic therapies.
Advancements in biotechnology: Technological breakthroughs in cell line engineering, process development, and analytical technologies are enabling the production of more complex and effective biologics.
Outsourcing trend: Biopharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to leverage their expertise and reduce operational costs.
Regulatory support: Governments worldwide are actively supporting the development and manufacturing of biologics through various incentives and regulatory approvals.
Challenges in the Biologics CDMO Market Sector
The Biologics CDMO market faces several challenges, including:
Stringent regulatory requirements: Meeting stringent regulatory standards for quality, safety, and efficacy adds to the cost and complexity of manufacturing.
Supply chain disruptions: Global supply chain disruptions can impact the availability of raw materials and other essential components.
Intense competition: The market is characterized by intense competition among established and emerging CDMOs, requiring continuous innovation and cost optimization. This pressure can impact profitability.
Emerging Opportunities in Biologics CDMO Market
Several emerging opportunities exist in the Biologics CDMO market:
Cell and gene therapies: The rapidly growing market for cell and gene therapies presents significant opportunities for CDMOs specializing in these advanced modalities.
Personalized medicine: The increasing demand for personalized medicine and targeted therapies opens new avenues for CDMOs to develop customized manufacturing solutions.
Emerging markets: Expanding into emerging markets with growing healthcare spending and increasing demand for biologics provides substantial growth potential.
Leading Players in the Biologics CDMO Market Market
- Toyobo Co Limited
- AGC Biologics
- Lonza Group
- Binex Co Limited
- Rentschler Biotechnologies
- Wuxi Biologics
- AbbVie Contract Manufacturing
- Parexel International Corporation
- Sandoz Biopharmaceuticals (Novartis AG)
- Catalent Inc
- JRS Pharma
- Fujifilm Diosynth Biotechnologies USA Inc
- Samsung Biologics
- Boehringer Ingelheim Group
- Icon PLC
Key Developments in Biologics CDMO Market Industry
- December 2021: AstraZeneca and Samsung Biologics expanded their strategic partnership, including manufacturing of a cancer immunotherapy product worth approximately USD 380 Million.
- March 2022: Oasmia Pharmaceutical AB and Lonza signed a large-scale manufacturing agreement for a drug candidate.
- April 2022: FUJIFILM Corporation completed the acquisition of a cell therapy manufacturing facility from Atara Biotherapeutics Inc., expanding its CDMO capabilities.
Future Outlook for Biologics CDMO Market Market
The Biologics CDMO market is poised for continued robust growth, driven by the increasing demand for biologics, technological advancements, and strategic partnerships. The expanding market for advanced therapies, such as cell and gene therapies, presents significant opportunities for CDMOs to expand their service offerings and capture market share. Strategic acquisitions and collaborations will continue to shape the competitive landscape, driving innovation and efficiency improvements. The focus on digitalization and data analytics will further enhance manufacturing processes and decision-making. The market's future outlook remains positive, with substantial growth potential across various segments and geographical regions.
Biologics CDMO Market Segmentation
-
1. Type
- 1.1. Mammalian
- 1.2. Non-mammalian (Microbial)
-
2. Product Type
-
2.1. Biologics
- 2.1.1. Monoclon
- 2.1.2. Recombinant Proteins
- 2.1.3. Antisense and Molecular Therapy
- 2.1.4. Vaccines
- 2.1.5. Other Biologics
- 2.2. Biosimilars
-
2.1. Biologics
Biologics CDMO Market Segmentation By Geography
- 1. North America
- 2. Europe
- 3. Asia
- 4. Australia and New Zealand
- 5. Latin America
- 6. Middle East and Africa
Biologics CDMO Market Regional Market Share
Geographic Coverage of Biologics CDMO Market
Biologics CDMO Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 12.78% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Access to New Technologies and Higher Speed of Execution Realized by CDMOs; Need for High Capital Investments to Develop Capabilities Has Led to Firms Choosing the Outsourcing Model; Lack of In-house Capacity among Emerging Drug Development Companies
- 3.3. Market Restrains
- 3.3.1. Presence of Alternative Printing Technology
- 3.4. Market Trends
- 3.4.1. CDMOs’ Access to New Technologies and Higher Speed of Execution Driving Market Growth
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Mammalian
- 5.1.2. Non-mammalian (Microbial)
- 5.2. Market Analysis, Insights and Forecast - by Product Type
- 5.2.1. Biologics
- 5.2.1.1. Monoclon
- 5.2.1.2. Recombinant Proteins
- 5.2.1.3. Antisense and Molecular Therapy
- 5.2.1.4. Vaccines
- 5.2.1.5. Other Biologics
- 5.2.2. Biosimilars
- 5.2.1. Biologics
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia
- 5.3.4. Australia and New Zealand
- 5.3.5. Latin America
- 5.3.6. Middle East and Africa
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. North America Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. Mammalian
- 6.1.2. Non-mammalian (Microbial)
- 6.2. Market Analysis, Insights and Forecast - by Product Type
- 6.2.1. Biologics
- 6.2.1.1. Monoclon
- 6.2.1.2. Recombinant Proteins
- 6.2.1.3. Antisense and Molecular Therapy
- 6.2.1.4. Vaccines
- 6.2.1.5. Other Biologics
- 6.2.2. Biosimilars
- 6.2.1. Biologics
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. Europe Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. Mammalian
- 7.1.2. Non-mammalian (Microbial)
- 7.2. Market Analysis, Insights and Forecast - by Product Type
- 7.2.1. Biologics
- 7.2.1.1. Monoclon
- 7.2.1.2. Recombinant Proteins
- 7.2.1.3. Antisense and Molecular Therapy
- 7.2.1.4. Vaccines
- 7.2.1.5. Other Biologics
- 7.2.2. Biosimilars
- 7.2.1. Biologics
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. Asia Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. Mammalian
- 8.1.2. Non-mammalian (Microbial)
- 8.2. Market Analysis, Insights and Forecast - by Product Type
- 8.2.1. Biologics
- 8.2.1.1. Monoclon
- 8.2.1.2. Recombinant Proteins
- 8.2.1.3. Antisense and Molecular Therapy
- 8.2.1.4. Vaccines
- 8.2.1.5. Other Biologics
- 8.2.2. Biosimilars
- 8.2.1. Biologics
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Australia and New Zealand Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. Mammalian
- 9.1.2. Non-mammalian (Microbial)
- 9.2. Market Analysis, Insights and Forecast - by Product Type
- 9.2.1. Biologics
- 9.2.1.1. Monoclon
- 9.2.1.2. Recombinant Proteins
- 9.2.1.3. Antisense and Molecular Therapy
- 9.2.1.4. Vaccines
- 9.2.1.5. Other Biologics
- 9.2.2. Biosimilars
- 9.2.1. Biologics
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Latin America Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Type
- 10.1.1. Mammalian
- 10.1.2. Non-mammalian (Microbial)
- 10.2. Market Analysis, Insights and Forecast - by Product Type
- 10.2.1. Biologics
- 10.2.1.1. Monoclon
- 10.2.1.2. Recombinant Proteins
- 10.2.1.3. Antisense and Molecular Therapy
- 10.2.1.4. Vaccines
- 10.2.1.5. Other Biologics
- 10.2.2. Biosimilars
- 10.2.1. Biologics
- 10.1. Market Analysis, Insights and Forecast - by Type
- 11. Middle East and Africa Biologics CDMO Market Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Type
- 11.1.1. Mammalian
- 11.1.2. Non-mammalian (Microbial)
- 11.2. Market Analysis, Insights and Forecast - by Product Type
- 11.2.1. Biologics
- 11.2.1.1. Monoclon
- 11.2.1.2. Recombinant Proteins
- 11.2.1.3. Antisense and Molecular Therapy
- 11.2.1.4. Vaccines
- 11.2.1.5. Other Biologics
- 11.2.2. Biosimilars
- 11.2.1. Biologics
- 11.1. Market Analysis, Insights and Forecast - by Type
- 12. Competitive Analysis
- 12.1. Global Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Toyobo Co Limited
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 AGC Biologics
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 Lonza Group
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 Binex Co Limited
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 Rentschler Biotechnologies
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 Wuxi Biologics
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 AbbVie Contract Manufacturing*List Not Exhaustive
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 Parexel International Corporation
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.9 Sandoz Biopharmaceuticals (Novartis AG)
- 12.2.9.1. Overview
- 12.2.9.2. Products
- 12.2.9.3. SWOT Analysis
- 12.2.9.4. Recent Developments
- 12.2.9.5. Financials (Based on Availability)
- 12.2.10 Catalent Inc
- 12.2.10.1. Overview
- 12.2.10.2. Products
- 12.2.10.3. SWOT Analysis
- 12.2.10.4. Recent Developments
- 12.2.10.5. Financials (Based on Availability)
- 12.2.11 JRS Pharma
- 12.2.11.1. Overview
- 12.2.11.2. Products
- 12.2.11.3. SWOT Analysis
- 12.2.11.4. Recent Developments
- 12.2.11.5. Financials (Based on Availability)
- 12.2.12 Fujifilm Diosynth Biotechnologies USA Inc
- 12.2.12.1. Overview
- 12.2.12.2. Products
- 12.2.12.3. SWOT Analysis
- 12.2.12.4. Recent Developments
- 12.2.12.5. Financials (Based on Availability)
- 12.2.13 Samsung Biologics
- 12.2.13.1. Overview
- 12.2.13.2. Products
- 12.2.13.3. SWOT Analysis
- 12.2.13.4. Recent Developments
- 12.2.13.5. Financials (Based on Availability)
- 12.2.14 Boehringer Ingelheim Group
- 12.2.14.1. Overview
- 12.2.14.2. Products
- 12.2.14.3. SWOT Analysis
- 12.2.14.4. Recent Developments
- 12.2.14.5. Financials (Based on Availability)
- 12.2.15 Icon PLC
- 12.2.15.1. Overview
- 12.2.15.2. Products
- 12.2.15.3. SWOT Analysis
- 12.2.15.4. Recent Developments
- 12.2.15.5. Financials (Based on Availability)
- 12.2.1 Toyobo Co Limited
List of Figures
- Figure 1: Global Biologics CDMO Market Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: North America Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 3: North America Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 4: North America Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 5: North America Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 6: North America Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 7: North America Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
- Figure 8: Europe Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 9: Europe Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 10: Europe Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 11: Europe Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 12: Europe Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 13: Europe Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
- Figure 14: Asia Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 15: Asia Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 16: Asia Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 17: Asia Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 18: Asia Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 19: Asia Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
- Figure 20: Australia and New Zealand Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 21: Australia and New Zealand Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 22: Australia and New Zealand Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 23: Australia and New Zealand Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 24: Australia and New Zealand Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 25: Australia and New Zealand Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
- Figure 26: Latin America Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 27: Latin America Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 28: Latin America Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 29: Latin America Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 30: Latin America Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 31: Latin America Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
- Figure 32: Middle East and Africa Biologics CDMO Market Revenue (Million), by Type 2025 & 2033
- Figure 33: Middle East and Africa Biologics CDMO Market Revenue Share (%), by Type 2025 & 2033
- Figure 34: Middle East and Africa Biologics CDMO Market Revenue (Million), by Product Type 2025 & 2033
- Figure 35: Middle East and Africa Biologics CDMO Market Revenue Share (%), by Product Type 2025 & 2033
- Figure 36: Middle East and Africa Biologics CDMO Market Revenue (Million), by Country 2025 & 2033
- Figure 37: Middle East and Africa Biologics CDMO Market Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 2: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 3: Global Biologics CDMO Market Revenue Million Forecast, by Region 2020 & 2033
- Table 4: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 5: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 6: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
- Table 7: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 8: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 9: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
- Table 10: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 11: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 12: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
- Table 13: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 14: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 15: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
- Table 16: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 17: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 18: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
- Table 19: Global Biologics CDMO Market Revenue Million Forecast, by Type 2020 & 2033
- Table 20: Global Biologics CDMO Market Revenue Million Forecast, by Product Type 2020 & 2033
- Table 21: Global Biologics CDMO Market Revenue Million Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Biologics CDMO Market?
The projected CAGR is approximately 12.78%.
2. Which companies are prominent players in the Biologics CDMO Market?
Key companies in the market include Toyobo Co Limited, AGC Biologics, Lonza Group, Binex Co Limited, Rentschler Biotechnologies, Wuxi Biologics, AbbVie Contract Manufacturing*List Not Exhaustive, Parexel International Corporation, Sandoz Biopharmaceuticals (Novartis AG), Catalent Inc, JRS Pharma, Fujifilm Diosynth Biotechnologies USA Inc, Samsung Biologics, Boehringer Ingelheim Group, Icon PLC.
3. What are the main segments of the Biologics CDMO Market?
The market segments include Type, Product Type.
4. Can you provide details about the market size?
The market size is estimated to be USD 15.32 Million as of 2022.
5. What are some drivers contributing to market growth?
Access to New Technologies and Higher Speed of Execution Realized by CDMOs; Need for High Capital Investments to Develop Capabilities Has Led to Firms Choosing the Outsourcing Model; Lack of In-house Capacity among Emerging Drug Development Companies.
6. What are the notable trends driving market growth?
CDMOs’ Access to New Technologies and Higher Speed of Execution Driving Market Growth.
7. Are there any restraints impacting market growth?
Presence of Alternative Printing Technology.
8. Can you provide examples of recent developments in the market?
April 2022 - FUJIFILM Corporation announced that it had completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics Inc. The facility, located in Thousand Oaks, California, will be operated as part of FUJIFILM DiosynthBiotechnologies' global network, a subsidiary of FUJIFILM Corporation and a world-leading contract development and manufacturing organization (CDMO).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Biologics CDMO Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Biologics CDMO Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Biologics CDMO Market?
To stay informed about further developments, trends, and reports in the Biologics CDMO Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence